Zevra Therapeutics (ZVRA) Accumulated Expenses (2014 - 2024)

Zevra Therapeutics has reported Accumulated Expenses for 11 years, with the latest figure at $6.1 million in Q4 2024.

• For the quarter ending Q4 2024, Accumulated Expenses fell 42.59% year-over-year to $6.1 million; the trailing twelve-month figure through Dec 2024 stood at $6.1 million (down 42.59% YoY), and the FY2024 full-year result was $6.1 million, down 42.59% from the prior year.
• Accumulated Expenses for Q4 2024 stood at $6.1 million, down from $10.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $10.7 million in Q4 2023, with the low at $53000.0 in Q4 2020.
• Historically, Accumulated Expenses has averaged $3.8 million across 5 years, with a median of $1.7 million in 2022.
• Annual changes were most pronounced in 2020 — Accumulated Expenses slumped 92.43% — and 2021, when it jumped 1220.75%.
• Zevra Therapeutics' Accumulated Expenses stood at $53000.0 in 2020, then jumped by 1220.75% to $700000.0 in 2021, then soared by 139.0% to $1.7 million in 2022, then surged by 537.84% to $10.7 million in 2023, then sank by 42.59% to $6.1 million in 2024.
• The last three Accumulated Expenses figures came in at $6.1 million (Q4 2024), $10.7 million (Q4 2023), and $1.7 million (Q4 2022), per Business Quant data.